FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205557986> ?p ?o ?g. }

• W3205557986 endingPage "204062072110489" @default.
• W3205557986 startingPage "204062072110489" @default.
• W3205557986 abstract "Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) is now recognized by the World Health Organization as an independent entity. PMBCL has clinicopathologic features that are separate from systemic DLBCL and harbors some biologic characteristics which overlap with nodular sclerosing classic Hodgkin's lymphoma (cHL). Similar to cHL, copy number alterations of 9p24.1 are frequently seen in PMBCL, which leads to increased expression of key genes in the region, including programmed death-ligand 1( PD-L1), PD-L2, and JAK2. In addition, PMBCL cells express CD30 in a mostly patchy fashion. In the upfront setting, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (i.e., DA-EPOCH-R) is the only regimen that has been shown in a prospective setting to result in outstanding outcomes without consolidative radiation to the mediastinum, with a 5-year event-free survival rate of 93% and overall survival rate of 97%. Thus, in recent years, DA-EPOCH-R has been recognized as the preferred frontline regimen. Despite the encouraging results in the frontline setting, the outcomes in the relapsed/refractory setting remain poor. The current approach of salvage chemotherapy followed by autologous stem cell transplantation, as used in patients with DLBCL, does not result in high rates of cure in patients with rrPMBCL. In recent years, the characteristic molecular features identified in PMBCL have provided more treatment opportunities for this patient population. In the relapsed setting, single-agent PD-1 inhibitor pembrolizumab have demonstrated high and durable remission rates. Despite the expression of CD30, the CD30 antibody drug-conjugate brentuximab vedotin (BV) as a single agent has been deemed inactive in this disease. On the contrary, the combinations of BV and PD-1 inhibitor have shown higher response rates than PD-1 inhibitor alone. Moreover, anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has been positioned as another successful strategy for patients with rrPMBCL. Axicabtagene ciloleucel and lisocabtagene maraleucel are two products used in rrPMBCL." @default.
• W3205557986 created "2021-10-25" @default.
• W3205557986 creator A5050290286 @default.
• W3205557986 creator A5082487188 @default.
• W3205557986 date "2021-01-01" @default.
• W3205557986 modified "2023-10-09" @default.
• W3205557986 title "Current and emerging treatment options in primary mediastinal B-cell lymphoma" @default.
• W3205557986 cites W1536794291 @default.
• W3205557986 cites W1884420797 @default.
• W3205557986 cites W1914909684 @default.
• W3205557986 cites W1970214140 @default.
• W3205557986 cites W1972179222 @default.
• W3205557986 cites W1986354050 @default.
• W3205557986 cites W1995939575 @default.
• W3205557986 cites W2001196047 @default.
• W3205557986 cites W2011228017 @default.
• W3205557986 cites W2038070878 @default.
• W3205557986 cites W2047867934 @default.
• W3205557986 cites W2060466778 @default.
• W3205557986 cites W2062486240 @default.
• W3205557986 cites W2065575863 @default.
• W3205557986 cites W2083715503 @default.
• W3205557986 cites W2084201114 @default.
• W3205557986 cites W2102311782 @default.
• W3205557986 cites W2105114563 @default.
• W3205557986 cites W2111500154 @default.
• W3205557986 cites W2113332344 @default.
• W3205557986 cites W2115774433 @default.
• W3205557986 cites W2116867723 @default.
• W3205557986 cites W2125616358 @default.
• W3205557986 cites W2128627706 @default.
• W3205557986 cites W2139952236 @default.
• W3205557986 cites W2143118351 @default.
• W3205557986 cites W2144209063 @default.
• W3205557986 cites W2152006714 @default.
• W3205557986 cites W2265995298 @default.
• W3205557986 cites W2310716991 @default.
• W3205557986 cites W2337659275 @default.
• W3205557986 cites W2462981464 @default.
• W3205557986 cites W2473498748 @default.
• W3205557986 cites W2483997783 @default.
• W3205557986 cites W2504623699 @default.
• W3205557986 cites W2593462836 @default.
• W3205557986 cites W2594602128 @default.
• W3205557986 cites W2596837024 @default.
• W3205557986 cites W2609973112 @default.
• W3205557986 cites W2764339126 @default.
• W3205557986 cites W2765344664 @default.
• W3205557986 cites W2765486607 @default.
• W3205557986 cites W2773804840 @default.
• W3205557986 cites W2780959200 @default.
• W3205557986 cites W2801174360 @default.
• W3205557986 cites W2967569980 @default.
• W3205557986 cites W2970124991 @default.
• W3205557986 cites W2979952645 @default.
• W3205557986 cites W2996472072 @default.
• W3205557986 cites W3039967857 @default.
• W3205557986 cites W3082855561 @default.
• W3205557986 cites W3092522602 @default.
• W3205557986 cites W3095514856 @default.
• W3205557986 cites W3126620286 @default.
• W3205557986 cites W3154411763 @default.
• W3205557986 cites W94592798 @default.
• W3205557986 doi "https://doi.org/10.1177/20406207211048959" @default.
• W3205557986 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8511915" @default.
• W3205557986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34659697" @default.
• W3205557986 hasPublicationYear "2021" @default.
• W3205557986 type Work @default.
• W3205557986 sameAs 3205557986 @default.
• W3205557986 citedByCount "11" @default.
• W3205557986 countsByYear W32055579862021 @default.
• W3205557986 countsByYear W32055579862022 @default.
• W3205557986 countsByYear W32055579862023 @default.
• W3205557986 crossrefType "journal-article" @default.
• W3205557986 hasAuthorship W3205557986A5050290286 @default.
• W3205557986 hasAuthorship W3205557986A5082487188 @default.
• W3205557986 hasBestOaLocation W32055579861 @default.
• W3205557986 hasConcept C121332964 @default.
• W3205557986 hasConcept C126322002 @default.
• W3205557986 hasConcept C1276947 @default.
• W3205557986 hasConcept C141071460 @default.
• W3205557986 hasConcept C143998085 @default.
• W3205557986 hasConcept C150846664 @default.
• W3205557986 hasConcept C2776694085 @default.
• W3205557986 hasConcept C2776755627 @default.
• W3205557986 hasConcept C2779338263 @default.
• W3205557986 hasConcept C2779429289 @default.
• W3205557986 hasConcept C2780317896 @default.
• W3205557986 hasConcept C2780653079 @default.
• W3205557986 hasConcept C2781413609 @default.
• W3205557986 hasConcept C2908647359 @default.
• W3205557986 hasConcept C71924100 @default.
• W3205557986 hasConcept C99454951 @default.
• W3205557986 hasConceptScore W3205557986C121332964 @default.
• W3205557986 hasConceptScore W3205557986C126322002 @default.
• W3205557986 hasConceptScore W3205557986C1276947 @default.
• W3205557986 hasConceptScore W3205557986C141071460 @default.
• W3205557986 hasConceptScore W3205557986C143998085 @default.

• next